| Literature DB >> 35619710 |
Ren-Qi Yao1,2, Chao Ren1,3, Li-Yu Zheng1, Zhao-Fan Xia2, Yong-Ming Yao1.
Abstract
Sepsis represents a life-threatening organ dysfunction due to an aberrant host response. Of note is that majority of patients have experienced a severe immune depression during and after sepsis, which is significantly correlated with the occurrence of nosocomial infection and higher risk of in-hospital death. Nevertheless, the clinical sign of sepsis-induced immune paralysis remains highly indetectable and ambiguous. Given that, specific yet robust biomarkers for monitoring the immune functional status of septic patients are of prominent significance in clinical practice. In turn, the stratification of a subgroup of septic patients with an immunosuppressive state will greatly contribute to the implementation of personalized adjuvant immunotherapy. In this review, we comprehensively summarize the mechanism of sepsis-associated immunosuppression at the cellular level and highlight the recent advances in immune monitoring approaches targeting the functional status of both innate and adaptive immune responses.Entities:
Keywords: adaptive immunity; biomarker; immune monitoring; immunosuppression; innate immunity; sepsis
Mesh:
Year: 2022 PMID: 35619710 PMCID: PMC9127053 DOI: 10.3389/fimmu.2022.891024
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Mechanisms and hallmarks of sepsis-induced immunosuppression. The innate and adaptive immune responses are significantly altered upon septic insults. With regard to innate immunity, sepsis induction results in a substantially increased apoptotic rate across various innate immune cell subsets, including neutrophils, monocytes, dendritic cells, and natural killer cells. Nevertheless, monocytic and granulocytic myeloid-derived suppressor cells have consistently undergone a profound augmentation, as evidenced by elevated circulating numbers in septic patients. As for adaptive immune response, both T and B lymphocytes are presented with significant apoptosis and functional anergy. Meanwhile, a phenotypical shift from effector subtypes to regulatory subtypes can be commonly observed in patients with sepsis. In turn, tremendous lymphopenia largely contributes to the development of sepsis-induced immunosuppression, thereby leading to increased risk of nosocomial infection, chronic critical illness, and even long-term mortality. Graph was created with BioRender.com. NETs, neutrophil extracellular traps; MDSCs, myeloid-derived suppressor cells; NK cells, natural killer cells; TCR, T cell receptor.
Immune monitoring indicators in human sepsis.
| Immune cell types | Category | Monitoring indicators | References | |
|---|---|---|---|---|
| Innate immunity | Neutrophils | Functional defects | Decreased bactericidal capacity | ( |
| Impaired chemotactic function | ( | |||
| Decreased spontaneous motility | ( | |||
| Excessive NET formation | ( | |||
| Upregulated expressions of CD64, PD-L1, sTREM-1, and HBP | ( | |||
| Alterations in subsets | Increased representation of immature circulating neutrophils | ( | ||
| Increased representation of OLFM4+ neutrophils | ( | |||
| Monocytes/macrophages | Functional defects | Diminished expression of mHLA-DR | ( | |
| Upregulation of PD-L1 | ( | |||
| Elevated MDW level | ( | |||
| Decreased production of TNF-α and IL-12 | ( | |||
| Increased secretory level of IL-10 | ( | |||
| Elevated circulating level of presepsin | ( | |||
| Elevated plasma level of ferritin, IL-6, IL-18, and sCD163 | ( | |||
| Impaired phagocytic capacity | ( | |||
| Alterations in subsets | Increased proportion of circulating CD14+HLA-DRlow monocytes | ( | ||
| Increased percentage of CD14-CD16+ patrolling monocytes | ( | |||
| MDSCs | Functional defects | Increased levels of S100A12, S100A8/A9, ARG1, and LOX-1 | ( | |
| Alterations in subsets | Expansion of G-MDSCs and M-MDSCs | ( | ||
| Dendritic cells | Functional defects | Down-regulated expression of HLA-DR | ( | |
| Enhanced production of IL-10 | ( | |||
| Elevated level of Blimp1 in circulating DCs | ( | |||
| Alterations in subsets | Reduction of pDCs and mDCs counts | ( | ||
| Increased representation of BTLA+ mDCs | ( | |||
| NK cells | Functional defects | Inhibitory secretion of IFN-γ and TNF-α | ( | |
| Impaired killing capacity | ( | |||
| Dampened expression of NCRs and NKG2 receptors | ( | |||
| Alterations in subsets | Reductions in both CD56hi and CD56low NK cells | ( | ||
| Increased percentage of PD-L1+ NK cells | ( | |||
| Adaptive immunity | Total lymphocytes | Persistently low counts of lymphocytes | ( | |
| T lymphocytes | Functional defects | Decreased TCR diversity | ( | |
| Impaired proliferative capacity | ( | |||
| Upregulation of exhaustion markers, including PD-1, 2B4, and BTLA | ( | |||
| Inhibitory capacity in releasing cytokines, including IL-2, IL-6, IFN-γ, and TNF-α | ( | |||
| Alterations in subsets | Reduced ratio of CD4+/CD8+ T cells | ( | ||
| Imbalanced ratio of Th1/Th2 | ( | |||
| Decreased representation of Th1, Th2, and Th17 subtypes | ( | |||
| Increased percentage of Tregs | ( | |||
| Reversed ratio of Th17/Treg | ( | |||
| Numerical loss of MAIT and γδ T cells | ( | |||
| B lymphocytes | Functional defects | Increased B cell exhaustion | ( | |
| Abnormal level of IgG | ( | |||
| Decreased level of IgM | ( | |||
| Alterations in subsets | Upregulated expression of CD80 and CD95 with downregulation of CD23 on B cells | ( | ||
| Decreases in percentages of circulating plasmablasts and memory B cells | ( | |||
| Increased percentage of Bregs | ( |
NETs, neutrophil extracellular traps; PD-L1, programmed cell death 1 ligand-1; TREM-1, triggering receptor expressed on myeloid cell-1; HBP, heparin-binding protein; OLFM4, olfactomedin-4; HLA-DR, human leukocyte antigen DR; MDW, monocyte distribution width; TNF-α, tumor necrosis factor-α; IL-12, interleukin 12; MDSCs, myeloid-derived suppressor cells; ARG1, arginase 1; LOX-1, lectin-type oxidized LDL receptor 1; G-MDSCs, granulocytic myeloid-derived suppressor cells; M-MDSCs, monocytic myeloid-derived suppressor cells; pDCs, plasmacytoid dendritic cells; mDCs, myeloid dendritic cells; BTLA, B and T lymphocyte attenuator; NK cells, natural killer cells; IFN-γ, interferon-γ; NCR, natural cytotoxicity receptors; NKG, NK group 2 member; TCR, T cell receptor; PD-1, programmed death-1; Th cells, helper T cells; Tregs, regulatory T cells; MAIT cells, mucosal-associated invariant T cells; γδ T cells, gamma delta T cells; Bregs, regulatory B cells.
Figure 2Approaches for immune monitoring of sepsis-associated immune dysfunction. Peripheral blood mononuclear cells or plasma isolated from septic patients are subjected to multiple immune monitoring assays in detecting the transcript and protein levels of various biomarkers that reflect functional status and subset alterations of certain immune cell types, including flow cytometry, ELISA, and qPCR. Moreover, transcriptomic- and proteomic-based sequencing technologies enable us to identify unique immune cell cluster and cell state, in association with sepsis-induced immunosuppression, including scRNA-seq and CytoF. The Graph was created with BioRender.com. ELISA, enzyme-linked immunosorbent assay; qPCR, quantitative real-time polymerase chain reaction; scRNA-seq, single-cell RNA sequencing; CytoF, cytometry with time-of-flight.